Dan Forche, CEO of PreludeDx, on Molecular Diagnostics, Precision Medicine for Breast Cancer

This year, PreludeDx, a leader in molecular diagnostics and precision medicine for early-stage breast cancer, signed a wrap-up health plan designed to increase the availability of DCISionRT to over 1000 payers and more than 15 million patients. DocWire News spoke with Dan Forche, CEO of PreludeDx, to learn more about DCISionRT, a biosignature that evaluates recurrence risk, and the impact PreludeDx stands to have on the treatment of breast cancer.